GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nautilus Biotechnology Inc (NAS:NAUT) » Definitions » Cash Flow from Investing

NAUT (Nautilus Biotechnology) Cash Flow from Investing : $63.41 Mil (TTM As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Nautilus Biotechnology Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2025, Nautilus Biotechnology spent $0.22 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $6.90 Mil on purchasing investments. It gained $26.63 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it received $0.00 Mil from other investing activities. In all, Nautilus Biotechnology gained $19.51 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2025.


Nautilus Biotechnology Cash Flow from Investing Historical Data

The historical data trend for Nautilus Biotechnology's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nautilus Biotechnology Cash Flow from Investing Chart

Nautilus Biotechnology Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Investing
-25.28 -138.96 -25.74 -43.74 66.25

Nautilus Biotechnology Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.35 14.29 -7.50 37.11 19.51

Nautilus Biotechnology Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Nautilus Biotechnology's Cash Flow from Investing for the fiscal year that ended in Dec. 2024 is calculated as:

Nautilus Biotechnology's Cash Flow from Investing for the quarter that ended in Mar. 2025 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $63.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nautilus Biotechnology  (NAS:NAUT) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Nautilus Biotechnology's purchase of property, plant, equipment for the three months ended in Mar. 2025 was $-0.22 Mil. It means Nautilus Biotechnology spent $0.22 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Nautilus Biotechnology's sale of property, plant, equipment for the three months ended in Mar. 2025 was $0.00 Mil. It means Nautilus Biotechnology gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Nautilus Biotechnology's purchase of business for the three months ended in Mar. 2025 was $0.00 Mil. It means Nautilus Biotechnology spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Nautilus Biotechnology's sale of business for the three months ended in Mar. 2025 was $0.00 Mil. It means Nautilus Biotechnology gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Nautilus Biotechnology's purchase of investment for the three months ended in Mar. 2025 was $-6.90 Mil. It means Nautilus Biotechnology spent {stock_data.stock.currency_symbol}}6.90 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Nautilus Biotechnology's sale of investment for the three months ended in Mar. 2025 was $26.63 Mil. It means Nautilus Biotechnology gained $26.63 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Nautilus Biotechnology's net Intangibles purchase and sale for the three months ended in Mar. 2025 was $0.00 Mil. It means Nautilus Biotechnology paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Nautilus Biotechnology's cash from discontinued investing activities for the three months ended in Mar. 2025 was 0.00 Mil. It means Nautilus Biotechnology paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Nautilus Biotechnology's cash from other investing activities for the three months ended in Mar. 2025 was $0.00 Mil. It means Nautilus Biotechnology received $0.00 Mil from other investing activities.


Nautilus Biotechnology Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Nautilus Biotechnology's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Nautilus Biotechnology Business Description

Traded in Other Exchanges
N/A
Address
2701 Eastlake Avenue East, Seattle, WA, USA, 98102
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
Executives
Sujal M Patel director, 10 percent owner, officer: CEO, President, and Secretary C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121
Mary E. Godwin officer: Senior VP, Operations 3101 WESTERN AVENUE, SEATTLE WA 98121
Michael Seth Altman director C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Subramanian Sankar officer: Senior VP, Product Development C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070
Gwen E Weld officer: Chief People Officer C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121
Anna Mowry officer: CFO and Treasurer C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070
Matthew B. Murphy officer: General Counsel C/O NAUTILUS BIOTECHNOLOGY, INC., 425 PONTIUS AVE N, STE 202, SEATTLE WA 98109
Karen Akinsanya director SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc director 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Matthew L. Posard director 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Matthew S Mcilwain director 1000 SECOND AVENUE, SUITE 3700, SEATTLE WA 98104
Marc L Andreessen 10 percent owner C/O ARNOLD & PORTER LLP, 3 EMBARCADERO CENTER 7TH FLOOR, SAN FRANCISCO CA 94111
Parag Mallick director, 10 percent owner, officer: Chief Scientist C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070